Abstract：
To evaluate the performance of complete-arch implant-supported fixed dental prostheses (FDPs) fabricated with polyetheretherketone (PEEK) and polyetherketoneketone (PEKK) framework in clinical cases.
This systematic review followed the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses and was registered in the International Prospective Register of Systematic Reviews with the number CRD42023399494. The electronic database PubMed, Cochrane Library and EBSCOhost were assessed for clinical research and reports on complete-arch implant-supported FDPs fabricated with PEEK and PEKK framework. Human studies with a minimum follow-up of 1 year and published in an English language were the only ones included.
The initial database and hand search provided 564 articles. Finally, 12 articles published between 2018 and 2022 were included in this systematic review. The mean follow-up ranged from 1 year to 6 years. The included studies reported 119 (114 PEEK, 5 PEKK) complete-arch implant-supported FDPs during 1 year follow-up. The cumulative survival rate of prostheses with PEEK as a framework was 97.3%. Prostheses fractures and complications were found with both PEEK and PEKK frameworks. No implant failure reported with both PEEK and PEKK prostheses.
In short-term follow-up, the complete-arch implant-supported FDPs with PEEK as a framework showed a good survival rate and acceptable health of the supporting tissues. The PEEK framework had shown adhesion issues as the most common prosthetic complication. Limited data were available on PEKK as framework material, so further long-term clinical trials are required.
This systematic review followed the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses and was registered in the International Prospective Register of Systematic Reviews with the number CRD42023399494. The electronic database PubMed, Cochrane Library and EBSCOhost were assessed for clinical research and reports on complete-arch implant-supported FDPs fabricated with PEEK and PEKK framework. Human studies with a minimum follow-up of 1 year and published in an English language were the only ones included.
The initial database and hand search provided 564 articles. Finally, 12 articles published between 2018 and 2022 were included in this systematic review. The mean follow-up ranged from 1 year to 6 years. The included studies reported 119 (114 PEEK, 5 PEKK) complete-arch implant-supported FDPs during 1 year follow-up. The cumulative survival rate of prostheses with PEEK as a framework was 97.3%. Prostheses fractures and complications were found with both PEEK and PEKK frameworks. No implant failure reported with both PEEK and PEKK prostheses.
In short-term follow-up, the complete-arch implant-supported FDPs with PEEK as a framework showed a good survival rate and acceptable health of the supporting tissues. The PEEK framework had shown adhesion issues as the most common prosthetic complication. Limited data were available on PEKK as framework material, so further long-term clinical trials are required.
摘要：
目的：评估用聚醚醚酮（PEEK）和聚醚酮酮（PEKK）框架制造的全弓种植体支持的固定假牙（FDP）在临床病例中的性能。
方法：本系统评价遵循系统评价和荟萃分析的首选报告项目指南，并在国际前瞻性系统评价登记册中注册，编号为CRD42023399494。电子数据库PubMed,对CochraneLibrary和EBSCOhost进行了临床研究评估，并报告了使用PEEK和PEKK框架制造的全足弓植入物支持的FDP。仅包括最少随访1年并以英语发表的人类研究。
结果：初始数据库和手工搜索提供了564篇文章。最后,本系统综述包括2018年至2022年发表的12篇文章。平均随访时间为1年至6年。纳入的研究报告了119项(114PEEK，5PEKK）在1年随访期间，完全牙弓植入物支持的FDP。以PEEK为骨架的假体的累积存活率为97.3%。PEEK和PEKK框架均发现假体骨折和并发症。PEEK和PEKK假体均未报告植入失败。
结论：在短期随访中，以PEEK为框架的全弓植入物支持的FDP显示出良好的存活率和可接受的支持组织健康状况.PEEK框架已显示出粘连问题是最常见的假体并发症。PEKK作为框架材料的数据有限，因此需要进一步的长期临床试验。
方法：本系统评价遵循系统评价和荟萃分析的首选报告项目指南，并在国际前瞻性系统评价登记册中注册，编号为CRD42023399494。电子数据库PubMed,对CochraneLibrary和EBSCOhost进行了临床研究评估，并报告了使用PEEK和PEKK框架制造的全足弓植入物支持的FDP。仅包括最少随访1年并以英语发表的人类研究。
结果：初始数据库和手工搜索提供了564篇文章。最后,本系统综述包括2018年至2022年发表的12篇文章。平均随访时间为1年至6年。纳入的研究报告了119项(114PEEK，5PEKK）在1年随访期间，完全牙弓植入物支持的FDP。以PEEK为骨架的假体的累积存活率为97.3%。PEEK和PEKK框架均发现假体骨折和并发症。PEEK和PEKK假体均未报告植入失败。
结论：在短期随访中，以PEEK为框架的全弓植入物支持的FDP显示出良好的存活率和可接受的支持组织健康状况.PEEK框架已显示出粘连问题是最常见的假体并发症。PEKK作为框架材料的数据有限，因此需要进一步的长期临床试验。
